DNDi Adds Affordable Ravidasvir Combo To Asian HCV Trials
This article was originally published in PharmAsia News
Executive Summary
DNDi is progressing its five-year initiative to improve access to affordable combination therapies for hepatitis C through new agreements for ravidasvir, which will be tested in trials in Malaysia and Thailand.
You may also be interested in...
Medicines Patent Pool Expands From HIV To Hepatitis C & TB, With 100 Projects On The Go
Drugs for hepatitis C and tuberculosis are now being licensed for generic production under the aegis of the Medicines Patent Pool, which says it now has 15 generic manufacturing partners working on more than 100 projects across the hepatitis C, TB and HIV areas.
Medicines Patent Pool Expands From HIV To Hepatitis C & TB, With 100 Projects On The Go
Drugs for hepatitis C and tuberculosis are now being licensed for generic production under the aegis of the Medicines Patent Pool, which says it now has 15 generic manufacturing partners working on more than 100 projects across the hepatitis C, TB and HIV areas.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.